Company: ENTXW
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001178913-25-002702
Chunk: 9

Company: Entera Bio Ltd.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 2
Chunk 9
---
 of 21 employees, of whom 19 are full-time employees, and all are based in Israel. In addition, we employ a number of specialized clinical, non-clinical, statistical, regulatory and development advisors based in the United States, the United Kingdom and Europe. Our operations are located in Jerusalem, Israel.

            21

Revenue

To date, we have not generated any revenue from sales of our products, and we do not expect to receive any revenue from our product candidates unless and until we obtain regulatory approval and successfully commercialize our products.

Research and Development Expenses

Research and development expenses consist of costs incurred for the development of our N-Tab™ technology platform and our product candidates. We expense both internal and external research and development expenses to operations for the periods in which they are incurred. We mapped the majority of external research and development costs incurred for our product candidates and development programs.

Internal and certain general external research and development expenses support multiple product candidate research and development programs, include:

                •
                
                  employee-related expenses, including salaries, bonuses and share-based compensation expenses for employees and service providers in the research and development function;

                •
                
                  costs associated with our research and development platform used across programs, process development, manufacturing, consulting fees and preclinical development for earlier stage programs and new technologies;

                •
                
                  expenses incurred in operating our laboratories including our small-scale manufacturing facility; and

                •
                
                  depreciation of research and development equipment, allocated overhead, rent and facilities-related expenses.

External research and development expenses for our main clinical development programs include:

                •
                
                  expenses incurred under agreements with CROs and investigative sites that conduct our clinical trials;

                •
                
                  other costs associated with pre-clinical and clinical activities;

                •
                
                  supply, development and manufacturing costs relating to clinical trial materials; and

                •
                
                  certain consulting and advisory services related to the program;

Research and development activities are the primary focus of our business. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase significantly in future periods as we advance our clinical candidates into later stages of clinical development and invest in additional preclinical candidates.

            22

Our research and development expenses may vary substantially from period to period based on the timing of our research and development activities, including due to the timing of initiation of clinical